Nordic Nanovector, Affibody to develop new radio-immunotherapies for multiple myeloma
Supported by a grant from Eurostars, the project will combine Affibody’s proprietary platforms with Nordic’s radioimmunotherapy technology. Sweden’s Vinnova and the Norwegian Research Council have awarded around €1m
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.